Document Detail


Markers of myocardial damage in acute coronary syndromes--therapeutic implications.
MedLine Citation:
PMID:  11557249     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients admitted with suspicion of an acute coronary syndrome (ACS) still constitute a diagnostic, prognostic and therapeutic challenge for the treating physician. The final diagnosis ranges from a noncardiac diagnosis to a full-blown myocardial infarction (MI). Biochemical markers of myocardial damage are essential for diagnosis and, especially troponin T and troponin I, have been shown to be valuable for early risk stratification and for selection of treatment in ACS. Patients identified to be at low risk of future cardiac events might be discharged early, and unnecessary investigations and treatments avoided. On the contrary, a more intense treatment can be started in patients identified to be at high risk. Unstable angina patients with, compared to without, elevation of troponin, have a more activated coagulation system and more frequently complex lesions and visible thrombus in their coronary arteries. Accordingly, antithrombotic and antiplatelet therapies, i.e. l.m.w heparin and GP IIb/IIIa receptor antagonists, have been proved to have beneficial effects in troponin positive patients, but little or no beneficial effects in troponin negative patients. Also, the beneficial effects of an invasive compared to a noninvasive approach seem to be much more pronounced in troponin positive patients. In patients with ST-elevation MI, an elevated troponin T level at admission are associated with an increased mortality. However, the therapeutic implications of this finding remain speculative. Patients admitted with chest pain and left bundle branch block (LBBB) and who develop an MI have a poor prognosis. Current guidelines in acute myocardial infarction state that these patients should receive thrombolysis. Despite that, only a minority of these patients do receive thrombolysis, most probably because of the great diagnostic uncertainty. Rapid testing with a cardiac marker, e.g. myoglobin, would most probably increase the proportion of patients with chest pain and LBBB who receive appropriate reperfusion treatment.
Authors:
B Lindahl
Related Documents :
16580659 - Diagnostic and prognostic role of cardiac troponin i (ctni) measured on the dpc immulite.
10187879 - Myocardial injury and left ventricular performance after subarachnoid hemorrhage.
9915769 - Cardiac troponin i gene knockout: a mouse model of myocardial troponin i deficiency.
9846519 - Serum cardiac troponin-t concentrations predict development of coronary artery disease ...
11294799 - Bedside multimarker testing for risk stratification in chest pain units: the chest pain...
21454139 - Use of the impella 2.5 for prophylactic circulatory support during elective high-risk p...
1530969 - Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fa...
7747689 - Predisposing risk factors and natural history of acute neurologic complications of left...
7228889 - Mechanism of cardiac contracture during anoxic arrest using cardiopulmonary by-pass.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinica chimica acta; international journal of clinical chemistry     Volume:  311     ISSN:  0009-8981     ISO Abbreviation:  Clin. Chim. Acta     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-14     Completed Date:  2001-11-01     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  1302422     Medline TA:  Clin Chim Acta     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Uppsala Cardiothoracic Centre, University Hospital, Uppsala, Sweden. Bertil.Lindahl@Card.Uas.Se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Biological Markers*
Bundle-Branch Block / diagnosis,  pathology,  therapy
Coronary Disease / diagnosis,  pathology,  therapy*
Electrocardiography
Humans
Myocardium / pathology*
Chemical
Reg. No./Substance:
0/Biological Markers

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent approaches in standardization of cardiac markers.
Next Document:  Prognostic role of hemostatic markers in acute coronary syndromes patients.